We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vertex, CRO Miscommunication Causes Backpedaling on CF Data
Vertex, CRO Miscommunication Causes Backpedaling on CF Data
June 6, 2012
Vertex’s cystic fibrosis (CF) program took a hit May 29 when the company announced it had mischaracterized data from an interim analysis of an ongoing Phase II study of Kalydeco and investigational drug VX-809.